Will AbbVie’s $10.9 Billion Acquisition Shape Its Dividend?
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
We examine altcoins with strong funding, evaluating how capital enables development pace, partnerships, and long-term roadmap execution.
17,339 articlesAbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
When the Federal Reserve sends a warning, investors watch closely. This guide breaks down why the stock market sounds...
Institutional moves can hint at mood, but they don’t guarantee gains. A large stake in Capri Holdings by DME Capital ...
A growing wave of city governments are terminating or pausing deals with FLOCK Safety after public concern over surve...
Oracle is reshaping its business from database software to a cloud infrastructure powerhouse, fueled by surging backl...
Geopolitics and energy markets collide when Iran tensions rise. This guide digs into how oil stocks historically resp...
As planet labs (pl) 2026 nears, investors weigh growth against costs in a fast-evolving space data market. This guide...
Federal health officials issued a warning about misleading statements from biotech billionaire Patrick Soon-Shiong re...
A 62-year-old retiree weighs a $500,000 Roth conversion over five years to reduce future RMDs, with an upfront tax bi...
As AI tools land in personal finance, results remain uneven for banks, fintechs, and everyday users. This report trac...
Analysts argue that fundamental shifts in lending rules and supervision have permanently altered housing finance. The...
Target Corp after latest earnings has investors weighing risk and reward. This guide breaks down what the numbers mea...